Literature DB >> 32870734

BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?

Mark C Markowski1, Emmanuel S Antonarakis1,2.   

Abstract

Entities:  

Year:  2020        PMID: 32870734      PMCID: PMC7655018          DOI: 10.1200/JCO.20.02246

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

1.  p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.

Authors:  Benjamin L Maughan; Liana B Guedes; Kenneth Boucher; Gaurav Rajoria; Zach Liu; Szczepan Klimek; Roberto Zoino; Emmanuel S Antonarakis; Tamara L Lotan
Journal:  Prostate Cancer Prostatic Dis       Date:  2018-01-04       Impact factor: 5.554

2.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Authors:  Joaquin Mateo; Suzanne Carreira; Shahneen Sandhu; Susana Miranda; Helen Mossop; Raquel Perez-Lopez; Daniel Nava Rodrigues; Dan Robinson; Aurelius Omlin; Nina Tunariu; Gunther Boysen; Nuria Porta; Penny Flohr; Alexa Gillman; Ines Figueiredo; Claire Paulding; George Seed; Suneil Jain; Christy Ralph; Andrew Protheroe; Syed Hussain; Robert Jones; Tony Elliott; Ursula McGovern; Diletta Bianchini; Jane Goodall; Zafeiris Zafeiriou; Chris T Williamson; Roberta Ferraldeschi; Ruth Riisnaes; Bernardette Ebbs; Gemma Fowler; Desamparados Roda; Wei Yuan; Yi-Mi Wu; Xuhong Cao; Rachel Brough; Helen Pemberton; Roger A'Hern; Amanda Swain; Lakshmi P Kunju; Rosalind Eeles; Gerhardt Attard; Christopher J Lord; Alan Ashworth; Mark A Rubin; Karen E Knudsen; Felix Y Feng; Arul M Chinnaiyan; Emma Hall; Johann S de Bono
Journal:  N Engl J Med       Date:  2015-10-29       Impact factor: 91.245

3.  Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.

Authors:  Wassim Abida; David Campbell; Akash Patnaik; Jeremy D Shapiro; Brieuc Sautois; Nicholas J Vogelzang; Eric G Voog; Alan H Bryce; Ray McDermott; Francesco Ricci; Julie Rowe; Jingsong Zhang; Josep Maria Piulats; Karim Fizazi; Axel S Merseburger; Celestia S Higano; Laurence E Krieger; Charles J Ryan; Felix Y Feng; Andrew D Simmons; Andrea Loehr; Darrin Despain; Melanie Dowson; Foad Green; Simon P Watkins; Tony Golsorkhi; Simon Chowdhury
Journal:  Clin Cancer Res       Date:  2020-02-21       Impact factor: 12.531

4.  Tumour lineage shapes BRCA-mediated phenotypes.

Authors:  Philip Jonsson; Chaitanya Bandlamudi; Michael L Cheng; Preethi Srinivasan; Shweta S Chavan; Noah D Friedman; Ezra Y Rosen; Allison L Richards; Nancy Bouvier; S Duygu Selcuklu; Craig M Bielski; Wassim Abida; Diana Mandelker; Ozge Birsoy; Liying Zhang; Ahmet Zehir; Mark T A Donoghue; José Baselga; Kenneth Offit; Howard I Scher; Eileen M O'Reilly; Zsofia K Stadler; Nikolaus Schultz; Nicholas D Socci; Agnes Viale; Marc Ladanyi; Mark E Robson; David M Hyman; Michael F Berger; David B Solit; Barry S Taylor
Journal:  Nature       Date:  2019-07-10       Impact factor: 49.962

5.  Genomic correlates of clinical outcome in advanced prostate cancer.

Authors:  Wassim Abida; Joanna Cyrta; Glenn Heller; Davide Prandi; Joshua Armenia; Ilsa Coleman; Marcin Cieslik; Matteo Benelli; Dan Robinson; Eliezer M Van Allen; Andrea Sboner; Tarcisio Fedrizzi; Juan Miguel Mosquera; Brian D Robinson; Navonil De Sarkar; Lakshmi P Kunju; Scott Tomlins; Yi Mi Wu; Daniel Nava Rodrigues; Massimo Loda; Anuradha Gopalan; Victor E Reuter; Colin C Pritchard; Joaquin Mateo; Diletta Bianchini; Susana Miranda; Suzanne Carreira; Pasquale Rescigno; Julie Filipenko; Jacob Vinson; Robert B Montgomery; Himisha Beltran; Elisabeth I Heath; Howard I Scher; Philip W Kantoff; Mary-Ellen Taplin; Nikolaus Schultz; Johann S deBono; Francesca Demichelis; Peter S Nelson; Mark A Rubin; Arul M Chinnaiyan; Charles L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-06       Impact factor: 11.205

6.  Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.

Authors:  Joaquin Mateo; Nuria Porta; Diletta Bianchini; Ursula McGovern; Tony Elliott; Robert Jones; Isabel Syndikus; Christy Ralph; Suneil Jain; Mohini Varughese; Omi Parikh; Simon Crabb; Angus Robinson; Duncan McLaren; Alison Birtle; Jacob Tanguay; Susana Miranda; Ines Figueiredo; George Seed; Claudia Bertan; Penny Flohr; Berni Ebbs; Pasquale Rescigno; Gemma Fowler; Ana Ferreira; Ruth Riisnaes; Rita Pereira; Andra Curcean; Robert Chandler; Matthew Clarke; Bora Gurel; Mateus Crespo; Daniel Nava Rodrigues; Shahneen Sandhu; Aude Espinasse; Peter Chatfield; Nina Tunariu; Wei Yuan; Emma Hall; Suzanne Carreira; Johann S de Bono
Journal:  Lancet Oncol       Date:  2019-12-02       Impact factor: 41.316

7.  The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.

Authors:  Yifan Wang; Andrea J Bernhardy; Cristina Cruz; John J Krais; Joseph Nacson; Emmanuelle Nicolas; Suraj Peri; Hanneke van der Gulden; Ingrid van der Heijden; Shane W O'Brien; Yong Zhang; Maribel I Harrell; Shawn F Johnson; Francisco J Candido Dos Reis; Paul D P Pharoah; Beth Karlan; Charlie Gourley; Diether Lambrechts; Georgia Chenevix-Trench; Håkan Olsson; Javier J Benitez; Mark H Greene; Martin Gore; Robert Nussbaum; Siegal Sadetzki; Simon A Gayther; Susanne K Kjaer; Alan D D'Andrea; Geoffrey I Shapiro; David L Wiest; Denise C Connolly; Mary B Daly; Elizabeth M Swisher; Peter Bouwman; Jos Jonkers; Judith Balmaña; Violeta Serra; Neil Johnson
Journal:  Cancer Res       Date:  2016-05-01       Impact factor: 12.701

8.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Authors:  Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson
Journal:  N Engl J Med       Date:  2016-07-06       Impact factor: 91.245

9.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

10.  Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.

Authors:  Wassim Abida; Akash Patnaik; David Campbell; Jeremy Shapiro; Alan H Bryce; Ray McDermott; Brieuc Sautois; Nicholas J Vogelzang; Richard M Bambury; Eric Voog; Jingsong Zhang; Josep M Piulats; Charles J Ryan; Axel S Merseburger; Gedske Daugaard; Axel Heidenreich; Karim Fizazi; Celestia S Higano; Laurence E Krieger; Cora N Sternberg; Simon P Watkins; Darrin Despain; Andrew D Simmons; Andrea Loehr; Melanie Dowson; Tony Golsorkhi; Simon Chowdhury
Journal:  J Clin Oncol       Date:  2020-08-14       Impact factor: 44.544

View more
  9 in total

1.  Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.

Authors:  Fadi Taza; Albert E Holler; Wei Fu; Hao Wang; Nabil Adra; Costantine Albany; Ryan Ashkar; Heather H Cheng; Alexandra O Sokolova; Neeraj Agarwal; Adam Kessel; Alan Bryce; Nellie Nafissi; Pedro Barata; A Oliver Sartor; Diogo Bastos; Oren Smaletz; Jacob E Berchuck; Mary-Ellen Taplin; Rahul Aggarwal; Cora N Sternberg; Panagiotis J Vlachostergios; Ajjai S Alva; Christopher Su; Catherine H Marshall; Emmanuel S Antonarakis
Journal:  JCO Precis Oncol       Date:  2021-07-22

2.  Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.

Authors:  Benjamin L Maughan; Emmanuel S Antonarakis
Journal:  Expert Opin Pharmacother       Date:  2021-04-07       Impact factor: 4.103

3.  Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.

Authors:  Tamara L Lotan; Harsimar B Kaur; Daniela C Salles; Sanjana Murali; Edward M Schaeffer; Jerry S Lanchbury; William B Isaacs; Robert Brown; Andrea L Richardson; Olivier Cussenot; Geraldine Cancel-Tassin; Kirsten M Timms; Emmanuel S Antonarakis
Journal:  Mod Pathol       Date:  2021-01-18       Impact factor: 8.209

4.  Companion Tumor Sequencing to Assess the Clinical Significance of Germline Sequencing in Children With Cancer.

Authors:  Tinaye Mutetwa; Catherine Goudie; William D Foulkes; Paz Polak
Journal:  JAMA Netw Open       Date:  2021-11-01

5.  PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations.

Authors:  Alexander von Werdt; Laura Brandt; Orlando D Schärer; Mark A Rubin
Journal:  JCO Precis Oncol       Date:  2021-10-22

6.  Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients.

Authors:  Wei Chen; Wei Xia; Song Xue; Hang Huang; Qi Lin; Yi Liu; Tongtong Liu; Yiqun Zhang; Panwang Zhang; Jianfei Wang; Yining Yang; Baijun Dong; Zhixian Yu
Journal:  Front Oncol       Date:  2022-02-17       Impact factor: 6.244

Review 7.  Emerging Biomarker-Guided Therapies in Prostate Cancer.

Authors:  Jasna E Deluce; Luisa Cardenas; Aly-Khan Lalani; Saman Maleki Vareki; Ricardo Fernandes
Journal:  Curr Oncol       Date:  2022-07-18       Impact factor: 3.109

Review 8.  BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside.

Authors:  Stergios Boussios; Elie Rassy; Michele Moschetta; Aruni Ghose; Sola Adeleke; Elisabet Sanchez; Matin Sheriff; Cyrus Chargari; Nicholas Pavlidis
Journal:  Cancers (Basel)       Date:  2022-08-11       Impact factor: 6.575

9.  Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA.

Authors:  Umang Swami; Raquel Mae Zimmerman; Roberto H Nussenzveig; Edgar Javier Hernandez; Yeonjung Jo; Nicolas Sayegh; Sergiusz Wesolowski; Lesli A Kiedrowski; Pedro C Barata; Gordon Howard Lemmon; Mehmet A Bilen; Elisabeth I Heath; Lakshminarayan Nandagopal; Hani M Babiker; Sumanta K Pal; Michael Lilly; Benjamin L Maughan; Benjamin Haaland; Mark Yandell; Oliver Sartor; Neeraj Agarwal
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.